App-Quantinova.ai

Non-classical activation of GLI1 as a therapeutic target for squamous cell lung cancer

Sahba Kasiri - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Development of small molecule direct AMPK activators for the treatment of cancer

Yasumichi Hitoshi - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

Arne Scholz - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

BAY-1143572

Cytoplasmic sequestration and autophagic degradation of ErbB receptors in HER2-driven cancer cells by small molecule Sigma1 modulators

Christina M. Maher - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Dual inhibition of PKC and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

Guillaume Carita - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sotrastaurin

ERK signal suppression and sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor

Yoshito Nakanishi - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Debio 1347

Dual targeting of ARK5 and CDK4 pathways with ON 123300 as a therapeutic strategy for colorectal carcinoma

Saikrishna A. Divakar - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Palbociclib

A novel compound ARN-3236 inhibits SIK2 and sensitizes ovarian cancer to paclitaxel

Jinhua Zhou - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Paclitaxel

Development and characterization of CCK2R-targeted SMDCs and identification of GIST as a potential therapeutic indication

Jonathan M. Shillingford - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

tubulysin

Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma

Neelesh Sharma - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Afatinib

Tumor cell death triggered by sustained IRES inhibition is a population-wide event involving a quorum-sensing mechanism in which putative tumor stem cells are eliminated along with their progeny

Christos Vaklavas - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Lurbinectedin specifically targets transcription in cancer cells, triggering DNA breaks and degradation of phosphorylated Pol II

Gema Santamaria-Nunez - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Lurbinectedin

Survivin-mediated radio-sensitization response in p53 mutant tumor cells

David J. Grdina - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Patient-derived adenoid cystic carcinoma xenografts to study molecular target modulation of tumor radiosensitivity

Prashanth Prabakaran - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The SMAC-Mimetic LCL161 exhibits strong synergy with radiation in vivo in head and neck squamous cell carcinoma by promoting tumor cell apoptosis

Linlin Yang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TL32711

Sensitization of prostate cancer to chemo-radiation by ribosomal protein S6 inhibition

Suleman S. Hussain - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Drug repurposing: Validation of sulfasalazine as a radiosensitizer in melanoma by blocking system Xc

Hilde Elise Frde - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sulfasalazine

Improving the efficacy of pretargeted radioimmunotherapy in preclinical murine models by utilizing bioorthogonal click chemistry

Jacob Houghton - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

CD47 signaling regulates a DNA damage response pathway by suppressing the expression of Schlafen-11 (SLFN11)

Anthony L. Schwartz - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

thrombospondin-1

Combined disulfiram and radiation therapy against atypical teratoid/rhabdoid tumor

Yeoung Eun Lee - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Disulfiram

Filters

41730 Abstracts